Edwin Alvarez, MD
Gynecologic Oncology · Sacramento, CANPI 1710197330
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,320 of the $11,871 with a category attached, or 95.4%. Eisai Inc. accounts for 62.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $6,651 and has fallen 96.4% since, to $241 in 2024.
Across 22 payments — averaging $539.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$7K
- GSK$2K
- EMD Serono Research & Development Institute, Inc.$2K
- Intuitive Surgical$163
- Merck$115
- Boston Scientific$80
- plus $129 from 4 others
Across 99 payments — averaging $13,542 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1M
- Genentech, Inc.$144K
- Genmab U.S., Inc.$74K
- Sumitomo Pharma America, Inc.$52K
- Trillium Therapeutics USA, LLC$37K
- Genmab A/s$26K
What the payments were for
- Consulting fees$11,32095%
- Food & beverage$4864%
- Education$651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 3 | $7,470 |
| GSK | 2 | $2,015 |
| EMD Serono Research & Development Institute, Inc. | 1 | $1,900 |
| Intuitive Surgical | 5 | $163 |
| Merck | 1 | $115 |
| Boston Scientific | 4 | $80 |
| Johnson & Johnson | 1 | $56 |
| Viiv Healthcare Company | 2 | $45 |
| Medline Industries LP | 1 | $15 |
| Pfizer | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,871 in reported general payments places this provider in the 75th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 24 | $61 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Sacramento
- Rebecca BrooksSacramento$133K
- Amanda Shepherd-LittlejohnSacramento$73K
- Melissa PhamSacramento$50K
- Alireza AbidiSacramento$13K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.